Format
Sort by
Items per page

Send to

Choose Destination

Best matches for barrett esophagus AND cancer risk:

Barrett esophagus and risk of esophageal cancer: a clinical review. Spechler SJ et al. JAMA. (2013)

Metformin use and the risk of esophageal cancer in Barrett esophagus. Agrawal S et al. South Med J. (2014)

Barrett's esophagus and cancer risk: how research advances can impact clinical practice. di Pietro M et al. Gut Liver. (2014)

Search results

Items: 1 to 20 of 1905

1.

Modeling Esophagitis Using Human Three-Dimensional Organotypic Culture System.

Laczkó D, Wang F, Johnson FB, Jhala N, Rosztóczy A, Ginsberg GG, Falk GW, Rustgi AK, Lynch JP.

Am J Pathol. 2017 Aug;187(8):1787-1799. doi: 10.1016/j.ajpath.2017.04.013. Epub 2017 Jun 13.

PMID:
28627413
2.

Barrett Esophagus.

Khieu M, Bhimji S.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2017 Jun-.
2017 Mar 25.

3.

Barrett Esophagus and Intramucosal Esophageal Adenocarcinoma.

Rajendra S, Sharma P.

Hematol Oncol Clin North Am. 2017 Jun;31(3):409-426. doi: 10.1016/j.hoc.2017.01.003. Epub 2017 Mar 22. Review.

PMID:
28501084
4.

CEACAM 6, a novel marker for the diagnosis of Barrett's esophagus.

Sharma N, Srivastava S, Kern F, Xian W, Yeoh KG, Ming T, McKeon F, Ho KY.

Dis Esophagus. 2017 Jul 1;30(7):1-5. doi: 10.1093/dote/dox026.

PMID:
28475729
5.

Morphological Features and Prognostic Significance of ARID1A-Deficient Esophageal Adenocarcinomas.

Drage MG, Tippayawong M, Agoston AT, Zheng Y, Bueno R, Hornick JL, Odze RD, Srivastava A.

Arch Pathol Lab Med. 2017 Jul;141(7):970-977. doi: 10.5858/arpa.2016-0318-OA. Epub 2017 Apr 25.

PMID:
28440661
6.

Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study.

Maddalo G, Fassan M, Cardin R, Piciocchi M, Marafatto F, Rugge M, Zaninotto G, Pozzan C, Castoro C, Ruol A, Biasiolo A, Farinati F.

J Clin Gastroenterol. 2017 Apr 18. doi: 10.1097/MCG.0000000000000790. [Epub ahead of print]

PMID:
28422774
7.

Helicobacter pylori and Barrett’s esophagus: a protective factor or a real cause?

Tomasello G, Giordano F, Mazzola M, Jurjus R, Jurjus A, Damiani P, Nobile S, Carini F, Leone A.

J Biol Regul Homeost Agents. 2017 Jan-Mar;31(1):9-15. Review.

PMID:
28337865
8.

Management of Gastroesophageal Junction Tumors.

Okereke IC.

Surg Clin North Am. 2017 Apr;97(2):265-275. doi: 10.1016/j.suc.2016.11.004. Epub 2017 Feb 14. Review.

PMID:
28325186
9.

Meta-analysis of biomarkers predicting risk of malignant progression in Barrett's oesophagus.

Altaf K, Xiong JJ, la Iglesia D, Hickey L, Kaul A.

Br J Surg. 2017 Apr;104(5):493-502. doi: 10.1002/bjs.10484. Review.

PMID:
28295252
10.

Endoscopic Management of Early Esophagogastric Cancer.

Rizvi QU, Balachandran A, Koay D, Sharma P, Singh R.

Surg Oncol Clin N Am. 2017 Apr;26(2):179-191. doi: 10.1016/j.soc.2016.10.007. Epub 2017 Feb 14. Review.

PMID:
28279463
11.

Screening and Preventive Strategies in Esophagogastric Cancer.

Zakko L, Lutzke L, Wang KK.

Surg Oncol Clin N Am. 2017 Apr;26(2):163-178. doi: 10.1016/j.soc.2016.10.004. Review.

PMID:
28279462
12.

The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.

Freedberg DE, Kim LS, Yang YX.

Gastroenterology. 2017 Mar;152(4):706-715. doi: 10.1053/j.gastro.2017.01.031. Review.

PMID:
28257716
13.

Recurrence of Barrett's Esophagus is Rare Following Endoscopic Eradication Therapy Coupled With Effective Reflux Control.

Komanduri S, Kahrilas PJ, Krishnan K, McGorisk T, Bidari K, Grande D, Keefer L, Pandolfino J.

Am J Gastroenterol. 2017 Apr;112(4):556-566. doi: 10.1038/ajg.2017.13. Epub 2017 Feb 14.

PMID:
28195178
14.

Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance.

Gatenby P, Bhattacharjee S, Wall C, Caygill C, Watson A.

World J Gastroenterol. 2016 Dec 28;22(48):10592-10600. doi: 10.3748/wjg.v22.i48.10592.

15.

Evolving management of metaplasia and dysplasia in Barrett's epithelium.

Evans RP, Mourad MM, Fisher SG, Bramhall SR.

World J Gastroenterol. 2016 Dec 21;22(47):10316-10324. doi: 10.3748/wjg.v22.i47.10316. Review.

16.

Population screening and treatment of Helicobacter pylori infection.

O'Connor A, O'Morain CA, Ford AC.

Nat Rev Gastroenterol Hepatol. 2017 Apr;14(4):230-240. doi: 10.1038/nrgastro.2016.195. Epub 2017 Jan 5. Review.

PMID:
28053340
17.

Risk Profiles for Barrett's Esophagus Differ between New and Prevalent, and Long- and Short-Segment Cases.

Tan MC, Murrey-Ittmann J, Nguyen T, Ketwaroo GA, El-Serag HB, Thrift AP.

PLoS One. 2016 Dec 30;11(12):e0169250. doi: 10.1371/journal.pone.0169250. eCollection 2016.

18.

Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.

Duits LC, van der Wel MJ, Cotton CC, Phoa KN, Ten Kate FJ, Seldenrijk CA, Offerhaus GJ, Visser M, Meijer SL, Mallant-Hent RC, Krishnadath KK, Pouw RE, Tijssen JG, Shaheen NJ, Bergman JJ.

Gastroenterology. 2017 Apr;152(5):993-1001.e1. doi: 10.1053/j.gastro.2016.12.008. Epub 2016 Dec 22.

PMID:
28012849
19.

Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy.

Thota PN, Vennalaganti P, Vennelaganti S, Young P, Gaddam S, Gupta N, Lieberman D, Sampliner R, Falk GW, Mathur S, Kennedy K, Cash BD, Moawad F, Bansal A, Spaander MC, Bruno MJ, Vargo J, Sharma P.

Gastroenterology. 2017 Apr;152(5):987-992. doi: 10.1053/j.gastro.2016.12.005. Epub 2016 Dec 15.

PMID:
27988383
20.

Current Endoscopic Approaches for the Treatment of Barrett Esophagus.

Brimhall B, Wani S.

J Clin Gastroenterol. 2016 Dec 14. [Epub ahead of print]

PMID:
27984396

Supplemental Content

Loading ...
Support Center